[Limit setting as an important task for nurses in ambulatory drug abuse treatment. More than handing out cups of methadone].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to C Loth.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The syndrome of ophthalmoplegia, ataxia and areflexia first mentioned in 1932 by Collier and in 1938 by van Bogaert was described more precisely in 1956 by Fisher. It represents a specific clinical entity and is considered to be a variant of idiopathic polyradiculoneuropathy (Guillain-Barré). The most striking features are external (sometimes also internal) ophthalmoplegia, hyporeflexia or areflexia and cerebellar ataxia. During the first days paresthesias are frequently present whereas other disturbances of sensibility are not common. Additional signs of neurological lesions may be observed in association with the syndrome. Spinal fluid shows the typical albumino-cytological dissociation. The disease is characterized by its benign course. The etiology remains unclear, therapy is not necessary.
1-Benzyl-1-(3-dimethylaminopropoxy)cycloheptane (bencyclane-hydrogen-fumarate; Fludilat) in a concentration of 10-2 M effects an increase in the O2 consumption and the formation of CO2 in a 10% bovine lens homogenate. This effect is even increased if the glucose-substrate supply is raised from 25 mM to 37 mM. Investigations on the concentrations at ATP, ADP and AMP show that bencyclane is able to stabilize the physiologic distribution pattern of the three free adenine nucleotides. Further, the observed changes in the distribution pattern indicated that the fumaric acid rest of bencyclane may serve as a substrate for this reaction in the same way as fumarate.